14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
EQ vs ANRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Alto Neuroscience Inc. (ANRO) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (34.1/100 SELL vs. 48.0/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. EQ trades at $1.12 (1.5x Forward P/E, 0.0% operating margin) versus ANRO at $26.51 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. ANRO 34.1/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -52.3% YoY).
Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile ANRO is in a Breakdown options structure phase (RSI 52.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EQ vs ANRO. Trailing 12-month operating profitability (EQ 0.0% vs ANRO 0.0%) and valuation multiples (EQ 1.5x vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EQ vs ANRO Key Questions & Quantitative Answers
As of Nov 19, 2026, Alto Neuroscience Inc. (ANRO) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (34.1/100 SELL vs. 48.0/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. EQ trades at $1.12 (1.5x Forward P/E, 0.0% operating margin) versus ANRO at $26.51 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. ANRO 34.1/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -52.3% YoY). Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile ANRO is in a Breakdown options structure phase (RSI 52.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ANRO leads the Growth & Scale pillar: EQ posts -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EQ generates $4.4M in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, EQ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.
EQ screens cheaper on headline valuation multiples. EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EQ (-59.0% ROE) versus ANRO (-46.7% ROE) capital efficiency.
In options market volatility and institutional positioning, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk). By comparison, ANRO carries 78.2% implied volatility (8th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.95β · 91% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.